Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership Mar 1, 2023 04:01AM
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Nov 14, 2022 04:05PM
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 1, 2022 04:30PM
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options Aug 15, 2022 04:05PM
VBL Therapeutics (VBLT) Announces 35% Workforce Reduction Aug 2, 2022 08:00AM


Aug 2, 2022 08:00AM VBL Therapeutics Announces Workforce Reduction
Jul 19, 2022 04:02PM VBL Therapeutics (VBLT) Reports Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec
Jul 19, 2022 04:01PM VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
May 31, 2022 08:00AM VBL Therapeutics to Participate in the Jefferies Healthcare Conference
May 17, 2022 07:00AM VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 08:00AM VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
May 3, 2022 08:00AM VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
Apr 28, 2022 04:05PM VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 26, 2022 08:00AM VBL Therapeutics (VBLT) Granted FDA Fast Track Designation for Ofra-Vec
Apr 26, 2022 08:00AM VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
Mar 31, 2022 08:00AM VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
Mar 23, 2022 07:00AM VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 14, 2022 09:57AM UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
Mar 14, 2022 08:00AM VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
Mar 8, 2022 08:00AM VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committ
Mar 3, 2022 08:00AM VBL Therapeutics to Participate at March Investor Conferences
Feb 15, 2022 04:05PM VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 2, 2022 08:00AM VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
Jan 18, 2022 08:04AM VBL Therapeutics (VBLT) Appoints Matthew Trudeau as Chief Commercial Officer
Jan 18, 2022 08:00AM VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer
Jan 6, 2022 08:10AM VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
Dec 20, 2021 07:30AM VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
Nov 15, 2021 07:30AM VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 8, 2021 08:00AM VBL Therapeutics to Report Third Quarter Financial Results on November 15
Oct 5, 2021 08:08AM VBL Therapeutics (VBLT) Appoints Sam Backenroth as CFO; Established US Operations
Oct 5, 2021 08:00AM VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
Sep 17, 2021 07:01AM VBL Therapeutics (VBLT) Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
Sep 17, 2021 07:00AM VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
Sep 10, 2021 07:00AM VBL Therapeutics to Present at Upcoming Conferences
Aug 30, 2021 07:01AM VBL Therapeutics (VBLT) Continues U.S. Enrollment in OVAL Phase 3 Trial Following FDA Authorization of Clinical Use of VB-111 Batches Produced in Modiin Facility
Aug 30, 2021 07:00AM VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
Aug 11, 2016 06:47AM BioLineRx (BLRX) Appoints New CEO
Aug 11, 2016 06:45AM BioLineRx Names Philip A. Serlin as Chief Executive Officer